Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUPAS17107 | Registry Identifier | ENCePP |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history.
The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Incidence of myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Incidence of stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Incidence of vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Time to event for composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Time to event for myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Time to event for all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months | |
| Incidence of dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date
Not provided
Not provided
Not provided
Patients prescribed ticagrelor in primary care, following Acute Cornoary Syndrome (ACS), for the first time (Dec 2010 - Mar 2015) in Cliniical Practice Research Datalink primary care data and followed for up to 12 months.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Luton | United Kingdom |
Not provided
| Label | URL |
|---|---|
| CSR Synopsis | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| From index date up to 12 months |
| Time to event for stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| From index date up to 12 months |
| Time to event for bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |